{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008303","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.707114+00:00","generated_at":"2026-06-17T10:26:10.835044+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pieris Pharma reports FY2022 net loss $33.3M; cash down to $59.2M; elarekibep data delayed to mid-2024","bullets":["Net loss $33.3M ($0.45/share) vs $45.7M ($0.71) in 2021; R&D expense fell to $53.0M from $66.7M.","Cash, cash equivalents and investments $59.2M at Dec 31, 2022, down from $117.8M; company funded for >12 months.","Elarekibep Phase 2a asthma data now expected mid-2024; AstraZeneca adding >100 sites to complete trial.","PRS-220 Phase 1 IPF topline results expected H2 2023; PRS-400 advancing toward candidate nomination in 2023.","Seagen initiated Phase 1 for SGN-BB228, triggering $5M milestone; Servier discontinued PRS-352."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008303","json":"https://secwatch.observer/filing/0001437749-23-008303.json","markdown":"https://secwatch.observer/filing/0001437749-23-008303.md","text":"https://secwatch.observer/filing/0001437749-23-008303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/0001437749-23-008303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/pirs20221130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:26:10.835044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ebceeb9802c45d05da3df647fc0a5595fb325c5","claim":"PALVELLA THERAPEUTICS, INC. reported financial results for fiscal year ended December 31, 2022.","evidence_excerpt":"reported financial results for the fiscal year ended December 31, 2022, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923008303/0001437749-23-008303-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}